Literature DB >> 30027144

Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors.

Kelly Klega1, Alma Imamovic-Tuco1, Gavin Ha1, Andrea N Clapp1, Stephanie Meyer1, Abigail Ward1, Catherine Clinton1, Anwesha Nag1, Eliezer Van Allen1, Elizabeth Mullen1, Steven G DuBois1, Katherine Janeway1, Matthew Meyerson1, Aaron R Thorner1, Brian D Crompton1.   

Abstract

Objective: Liquid biopsies are being rapidly used in adult cancers as new biomarkers of disease. Circulating tumor DNA (ctDNA) levels have been reported to be proportional to disease burden, correlate with treatment response, and predict relapse. However, little is known about how frequently ctDNA is detectable in pediatric patients with solid tumors. Therefore, we developed a next-generation sequencing approach to detect and quantify ctDNA in the blood of patients with the most common pediatric solid tumors.
Methods: Detection of ctDNA requires assays sensitive to somatic events typically observed in the cancer type being studied. In pediatric solid tumors, structural variants are more common than recurrent point mutations. We adapted an ultralow passage whole-genome sequencing approach to capture copy number variants and a hybrid capture sequencing assay to detect translocations in liquid biopsy samples from pediatric patients.
Results: Copy number changes seen by ultralow passage whole-genome sequencing enabled detection of ctDNA in patients with osteosarcoma, neuroblastoma, alveolar rhabdomyosarcoma, and Wilms tumor. In Ewing sarcoma, detection of the EWSR1 translocation was a more sensitive approach. For patients with samples collected at multiple time points, changes in ctDNA levels corresponded to treatment response. We also found that disease-specific genomic biomarkers of prognosis were detectable in ctDNA.
Conclusion: This study demonstrates that liquid biopsy approaches that detect somatic structural variants are well suited to pediatric solid tumors. We show that children with the most common solid tumor malignancies have detectable levels of ctDNA, which may be used to track disease response and identify genomic subclassifiers of disease. Efforts to profile larger collections of clinically annotated specimens are under way to validate the clinical use of these assays.

Entities:  

Year:  2018        PMID: 30027144      PMCID: PMC6049092          DOI: 10.1200/PO.17.00285

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


  53 in total

1.  Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

Authors:  Adrian G Sacher; Cloud Paweletz; Suzanne E Dahlberg; Ryan S Alden; Allison O'Connell; Nora Feeney; Stacy L Mach; Pasi A Jänne; Geoffrey R Oxnard
Journal:  JAMA Oncol       Date:  2016-08-01       Impact factor: 31.777

2.  Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas.

Authors:  Toshifumi Ozaki; Karl-Ludwig Schaefer; Daniel Wai; Horst Buerger; Silke Flege; Norbert Lindner; Matthias Kevric; Raihanatou Diallo; Agnes Bankfalvi; Christian Brinkschmidt; Heribert Juergens; Winfried Winkelmann; Barbara Dockhorn-Dworniczak; Stefan S Bielack; Christopher Poremba
Journal:  Int J Cancer       Date:  2002-12-01       Impact factor: 7.396

3.  DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma.

Authors:  M Tarkkanen; I Elomaa; C Blomqvist; A H Kivioja; P Kellokumpu-Lehtinen; T Böhling; J Valle; S Knuutila
Journal:  Int J Cancer       Date:  1999-04-20       Impact factor: 7.396

4.  Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark Krailo; Eugenie S Kleinerman; Donna Betcher; Mark L Bernstein; Ernest Conrad; William Ferguson; Mark Gebhardt; Allen M Goorin; Michael B Harris; John Healey; Andrew Huvos; Michael Link; Joseph Montebello; Helen Nadel; Michael Nieder; Judith Sato; Gene Siegal; Michael Weiner; Robert Wells; Lester Wold; Richard Womer; Holcombe Grier
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

5.  Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma.

Authors:  Jan Smida; Daniel Baumhoer; Michael Rosemann; Axel Walch; Stefan Bielack; Christopher Poremba; Klaus Remberger; Eberhard Korsching; Wolfram Scheurlen; Christian Dierkes; Stefan Burdach; Gernot Jundt; Michael J Atkinson; Michaela Nathrath
Journal:  Clin Cancer Res       Date:  2010-07-07       Impact factor: 12.531

6.  Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.

Authors:  Jennifer A Perry; Adam Kiezun; Peter Tonzi; Eliezer M Van Allen; Scott L Carter; Sylvan C Baca; Glenn S Cowley; Ami S Bhatt; Esther Rheinbay; Chandra Sekhar Pedamallu; Elena Helman; Amaro Taylor-Weiner; Aaron McKenna; David S DeLuca; Michael S Lawrence; Lauren Ambrogio; Carrie Sougnez; Andrey Sivachenko; Loren D Walensky; Nikhil Wagle; Jaume Mora; Carmen de Torres; Cinzia Lavarino; Simone Dos Santos Aguiar; Jose Andres Yunes; Silvia Regina Brandalise; Gabriela Elisa Mercado-Celis; Jorge Melendez-Zajgla; Rocío Cárdenas-Cardós; Liliana Velasco-Hidalgo; Charles W M Roberts; Levi A Garraway; Carlos Rodriguez-Galindo; Stacey B Gabriel; Eric S Lander; Todd R Golub; Stuart H Orkin; Gad Getz; Katherine A Janeway
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

7.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

8.  Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.

Authors:  Elin S Gray; Helen Rizos; Anna L Reid; Suzanah C Boyd; Michelle R Pereira; Johnny Lo; Varsha Tembe; James Freeman; Jenny H J Lee; Richard A Scolyer; Kelvin Siew; Chris Lomma; Adam Cooper; Muhammad A Khattak; Tarek M Meniawy; Georgina V Long; Matteo S Carlino; Michael Millward; Melanie Ziman
Journal:  Oncotarget       Date:  2015-12-08

9.  Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.

Authors:  Viktor A Adalsteinsson; Gavin Ha; Samuel S Freeman; Atish D Choudhury; Daniel G Stover; Heather A Parsons; Gregory Gydush; Sarah C Reed; Denisse Rotem; Justin Rhoades; Denis Loginov; Dimitri Livitz; Daniel Rosebrock; Ignaty Leshchiner; Jaegil Kim; Chip Stewart; Mara Rosenberg; Joshua M Francis; Cheng-Zhong Zhang; Ofir Cohen; Coyin Oh; Huiming Ding; Paz Polak; Max Lloyd; Sairah Mahmud; Karla Helvie; Margaret S Merrill; Rebecca A Santiago; Edward P O'Connor; Seong H Jeong; Rachel Leeson; Rachel M Barry; Joseph F Kramkowski; Zhenwei Zhang; Laura Polacek; Jens G Lohr; Molly Schleicher; Emily Lipscomb; Andrea Saltzman; Nelly M Oliver; Lori Marini; Adrienne G Waks; Lauren C Harshman; Sara M Tolaney; Eliezer M Van Allen; Eric P Winer; Nancy U Lin; Mari Nakabayashi; Mary-Ellen Taplin; Cory M Johannessen; Levi A Garraway; Todd R Golub; Jesse S Boehm; Nikhil Wagle; Gad Getz; J Christopher Love; Matthew Meyerson
Journal:  Nat Commun       Date:  2017-11-06       Impact factor: 14.919

10.  Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.

Authors:  Muhammed Murtaza; Sarah-Jane Dawson; Katherine Pogrebniak; Oscar M Rueda; Elena Provenzano; John Grant; Suet-Feung Chin; Dana W Y Tsui; Francesco Marass; Davina Gale; H Raza Ali; Pankti Shah; Tania Contente-Cuomo; Hossein Farahani; Karey Shumansky; Zoya Kingsbury; Sean Humphray; David Bentley; Sohrab P Shah; Matthew Wallis; Nitzan Rosenfeld; Carlos Caldas
Journal:  Nat Commun       Date:  2015-11-04       Impact factor: 14.919

View more
  29 in total

Review 1.  Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies.

Authors:  Samuel D Abbou; David S Shulman; Steven G DuBois; Brian D Crompton
Journal:  Pediatr Blood Cancer       Date:  2019-01-06       Impact factor: 3.167

2.  Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers.

Authors:  N Shukla; M F Levine; G Gundem; D Domenico; B Spitzer; N Bouvier; J E Arango-Ossa; D Glodzik; J S Medina-Martínez; U Bhanot; J Gutiérrez-Abril; Y Zhou; E Fiala; E Stockfisch; S Li; M I Rodriguez-Sanchez; T O'Donohue; C Cobbs; M H A Roehrl; J Benhamida; F Iglesias Cardenas; M Ortiz; M Kinnaman; S Roberts; M Ladanyi; S Modak; S Farouk-Sait; E Slotkin; M A Karajannis; F Dela Cruz; J Glade Bender; A Zehir; A Viale; M F Walsh; A L Kung; E Papaemmanuil
Journal:  Nat Commun       Date:  2022-05-18       Impact factor: 17.694

3.  Minimally invasive classification of paediatric solid tumours using reduced representation bisulphite sequencing of cell-free DNA: a proof-of-principle study.

Authors:  Ruben Van Paemel; Andries De Koker; Charlotte Vandeputte; Lieke van Zogchel; Tim Lammens; Geneviève Laureys; Jo Vandesompele; Gudrun Schleiermacher; Mathieu Chicard; Nadine Van Roy; Ales Vicha; G A M Tytgat; Nico Callewaert; Katleen De Preter; Bram De Wilde
Journal:  Epigenetics       Date:  2020-07-14       Impact factor: 4.528

4.  Optimizing Nanopore sequencing-based detection of structural variants enables individualized circulating tumor DNA-based disease monitoring in cancer patients.

Authors:  Jose Espejo Valle-Inclan; Christina Stangl; Anouk C de Jong; Lisanne F van Dessel; Markus J van Roosmalen; Jean C A Helmijr; Ivo Renkens; Roel Janssen; Sam de Blank; Chris J de Witte; John W M Martens; Maurice P H M Jansen; Martijn P Lolkema; Wigard P Kloosterman
Journal:  Genome Med       Date:  2021-05-18       Impact factor: 11.117

Review 5.  Circulating tumor DNA for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.

Authors:  Jordan Jones; Sarah Cain; Jonathan Pesic-Smith; Peter F M Choong; Andrew P Morokoff; Kate J Drummond; Gabriel Dabscheck
Journal:  J Neurooncol       Date:  2021-09-16       Impact factor: 4.130

6.  Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.

Authors:  David S Shulman; Kelly Klega; Alma Imamovic-Tuco; Andrea Clapp; Anwesha Nag; Aaron R Thorner; Eliezer Van Allen; Gavin Ha; Stephen L Lessnick; Richard Gorlick; Katherine A Janeway; Patrick J Leavey; Leo Mascarenhas; Wendy B London; Kieuhoa T Vo; Kimberly Stegmaier; David Hall; Mark D Krailo; Donald A Barkauskas; Steven G DuBois; Brian D Crompton
Journal:  Br J Cancer       Date:  2018-08-21       Impact factor: 7.640

7.  Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease.

Authors:  Matthew L Hemming; Kelly S Klega; Justin Rhoades; Gavin Ha; Kate E Acker; Jessica L Andersen; Edwin Thai; Anwesha Nag; Aaron R Thorner; Chandrajit P Raut; Suzanne George; Brian D Crompton
Journal:  JCO Precis Oncol       Date:  2019-01-24

Review 8.  Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy.

Authors:  Neetha Nanoth Vellichirammal; Nagendra K Chaturvedi; Shantaram S Joshi; Donald W Coulter; Chittibabu Guda
Journal:  Cancer Lett       Date:  2020-11-25       Impact factor: 9.756

9.  Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients.

Authors:  Elisa Izquierdo; Paula Proszek; Giulia Pericoli; Sara Temelso; Matthew Clarke; Diana M Carvalho; Alan Mackay; Lynley V Marshall; Fernando Carceller; Darren Hargrave; Birgitta Lannering; Zdenek Pavelka; Simon Bailey; Natacha Entz-Werle; Jacques Grill; Gilles Vassal; Daniel Rodriguez; Paul S Morgan; Tim Jaspan; Angela Mastronuzzi; Mara Vinci; Michael Hubank; Chris Jones
Journal:  Neurooncol Adv       Date:  2021-01-27

10.  A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas.

Authors:  Avanthi Tayi Shah; Tej D Azad; Marcus R Breese; Jacob J Chabon; Emily G Hamilton; Krystal Straessler; David M Kurtz; Stanley G Leung; Aviv Spillinger; Heng-Yi Liu; Inge H Behroozfard; Frederick M Wittber; Florette K Hazard; Soo-Jin Cho; Heike E Daldrup-Link; Kieuhoa T Vo; Arun Rangaswami; Allison Pribnow; Sheri L Spunt; Norman J Lacayo; Maximilian Diehn; Ash A Alizadeh; E Alejandro Sweet-Cordero
Journal:  Mol Cancer Ther       Date:  2021-08-05       Impact factor: 6.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.